001     857533
005     20240625095126.0
024 7 _ |a 10.1124/mol.117.110064
|2 doi
024 7 _ |a 0026-895X
|2 ISSN
024 7 _ |a 0026-895x
|2 ISSN
024 7 _ |a 1521-0111
|2 ISSN
024 7 _ |a pmid:29025967
|2 pmid
024 7 _ |a WOS:000415985000007
|2 WOS
024 7 _ |a altmetric:27519982
|2 altmetric
037 _ _ |a FZJ-2018-06524
082 _ _ |a 610
100 1 _ |a Schmidt, Axel
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Diminazene Is a Slow Pore Blocker of Acid-Sensing Ion Channel 1a (ASIC1a)
260 _ _ |a Bethesda, Md.
|c 2017
|b ASPET
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1547622858_3400
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Acid-sensing ion channels (ASICs) are neuronal receptors for extracellular protons. They contribute to the excitatory postsynaptic current and to the detection of painful acidosis. Moreover, they are activated during peripheral inflammation and acidosis associated with various neuronal disorders, such as stroke and neuroinflammation, rendering them interesting drug targets. Diminazene aceturate is a small-molecule inhibitor of ASICs with a reported apparent affinity in the low micromolar range, making it an interesting lead compound. It was reported that diminazene accelerates desensitization of ASICs, which was, however, not explained mechanistically. Furthermore, a binding site in a groove of the extracellular domain was proposed but not experimentally verified. In this study, we revisited the mechanism of inhibition by diminazene and its binding site on ASIC1a, the ASIC subunit with the greatest importance in the central nervous system. We show that diminazene slowly blocks ASIC1a, leading to the apparent acceleration of desensitization and underestimating its potency; we show that diminazene indeed has a submicromolar potency at ASIC1a (IC50 0.3 μM). Moreover, we show that the inhibition is voltage-dependent and competes with that by amiloride, a pore blocker of ASICs. Finally, we identify by molecular docking a binding site in the ion pore that we confirm by site-directed mutagenesis. In summary, our results show that diminazene blocks ASIC1a by a slow open-channel block and suggest that diminazene is an interesting lead compound for high-affinity blockers of ASICs.
536 _ _ |a 574 - Theory, modelling and simulation (POF3-574)
|0 G:(DE-HGF)POF3-574
|c POF3-574
|f POF III
|x 0
536 _ _ |a 511 - Computational Science and Mathematical Methods (POF3-511)
|0 G:(DE-HGF)POF3-511
|c POF3-511
|f POF III
|x 1
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Rossetti, Giulia
|0 P:(DE-Juel1)145921
|b 1
|u fzj
700 1 _ |a Joussen, Sylvia
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Gründer, Stefan
|0 P:(DE-HGF)0
|b 3
|e Corresponding author
773 _ _ |a 10.1124/mol.117.110064
|g Vol. 92, no. 6, p. 665 - 675
|0 PERI:(DE-600)1475030-2
|n 6
|p 665 - 675
|t Molecular pharmacology
|v 92
|y 2017
|x 1521-0111
856 4 _ |u https://juser.fz-juelich.de/record/857533/files/665.full-1.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/857533/files/665.full-1.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |p VDB
|o oai:juser.fz-juelich.de:857533
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)145921
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-574
|2 G:(DE-HGF)POF3-500
|v Theory, modelling and simulation
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
913 1 _ |a DE-HGF
|b Key Technologies
|1 G:(DE-HGF)POF3-510
|0 G:(DE-HGF)POF3-511
|2 G:(DE-HGF)POF3-500
|v Computational Science and Mathematical Methods
|x 1
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|l Supercomputing & Big Data
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL PHARMACOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)IAS-5-20120330
|k IAS-5
|l Computational Biomedicine
|x 0
920 1 _ |0 I:(DE-Juel1)JSC-20090406
|k JSC
|l Jülich Supercomputing Center
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)IAS-5-20120330
980 _ _ |a I:(DE-Juel1)JSC-20090406
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)INM-9-20140121


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21